# Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL

> **NCT03567876** · PHASE2 · COMPLETED · sponsor: **Fondazione Italiana Linfomi - ETS** · enrollment: 141 (actual)

## Conditions studied

- Lymphoma, Mantle-Cell

## Interventions

- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03567876
- **Lead sponsor:** Fondazione Italiana Linfomi - ETS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-03
- **Primary completion:** 2021-07-26
- **Final completion:** 2025-10-15
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2025-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03567876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03567876, "Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03567876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*